How can we meet the comprehensive data requirements for Joint Assessments, especially when they differ from national requirements?
How can we coordinate the timing of submissions and assessments across multiple countries?
How can we effectively engage with a diverse range of stakeholders, including national HTA bodies, healthcare providers, and patient organizations, to ensure their needs and perspectives are considered?
How can we balance the need for transparency in the assessment process with the protection of confidential business information and proprietary data?
How can we ensure clear and consistent communication and documentation throughout the Joint Assessment process to avoid misunderstandings and errors?
How can we manage the variability in how different Member States might accept and implement Joint Assessment recommendations, and how does this affect our market access strategies?

Dr. Stephanie Rosenfeld, Global Head Market Access and Evidence Based Medicine Strategy, Bayer AG
Inka Heikkinen, Regulatory Policy Lead (Director), Lundbeck
Anand Jha, Managing Director, ANSEA
Sandeep Kiri, UCB Global Payer Value Strategy – Head of Health Economics and HTA Evidence, UCB
Dr. Thomas Grub, Director Global Pricing & Market Access, medac GmbH

MORE VIDEOS

We would be pleased to welcome you to the Pharma Market Access & Research Summit. Secure your ticket here.